Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2005 Apr 20;64(12):1773–1779. doi: 10.1136/ard.2005.035279

Variations in performance characteristics of commercial enzyme immunoassay kits for detection of antineutrophil cytoplasmic antibodies: what is the optimal cut off?

J Holle 1, B Hellmich 1, M Backes 1, W Gross 1, E Csernok 1
PMCID: PMC1755320  PMID: 15843447

Abstract

Background: Previous studies have shown considerable variation in diagnostic performance of enzyme linked immunosorbent assays (ELISAs) for measuring antineutrophil cytoplasmic antibodies (ANCA) specific for proteinase 3 (PR3) and myeloperoxidase (MPO).

Objective: To analyse the performance characteristics of different commercially available direct ANCA ELISA kits.

Methods: ELISA kits for detecting PR3-ANCA and MPO-ANCA from 11 manufacturers were evaluated. Serum samples were taken from patients with Wegener's granulomatosis (15), microscopic polyangiitis (15), other vasculitides (10), and controls (40). Results were compared with data obtained by indirect immunofluorescence (IFT). The diagnostic performance of the tests was analysed and compared by receiver operating characteristic (ROC) curve analysis.

Results: Applying the manufacturers' cut off resulted in great variation in sensitivity of the commercial PR3-ANCA kits for diagnosing Wegener's granulomatosis (ranging from 13.3% to 66.7%), and of the MPO-ANCA kits for diagnosing microscopic polyangiitis (ranging from 26.7% to 66.7%). Specificities were relatively constant (from 96.0% to 100%). IFT was superior to all ELISAs (C-ANCA for Wegener's granulomatosis: sensitivity 73.3%, specificity 98%; P-ANCA for microscopic polyangiitis: sensitivity 86.7%, specificity 98%). The sensitivities of PR3-ANCA and MPO-ANCA ELISA kits were increased by lowering the cut off values. This reduced specificity but increased overall diagnostic performance.

Conclusions: The low sensitivity of some commercial kits reflects the high cut off levels recommended rather than methodological problems with the assays. Comparative analyses using sera from well characterised patients may help identify optimum cut off levels of commercial ANCA ELISA tests, resulting in better comparability of results among assays from different manufacturers.

Full Text

The Full Text of this article is available as a PDF (77.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boomsma M. M., Stegeman C. A., van der Leij M. J., Oost W., Hermans J., Kallenberg C. G., Limburg P. C., Tervaert J. W. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 2000 Sep;43(9):2025–2033. doi: 10.1002/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO;2-O. [DOI] [PubMed] [Google Scholar]
  2. Csernok E., Ahlquist D., Ullrich S., Gross W. L. A critical evaluation of commercial immunoassays for antineutrophil cytoplasmic antibodies directed against proteinase 3 and myeloperoxidase in Wegener's granulomatosis and microscopic polyangiitis. Rheumatology (Oxford) 2002 Nov;41(11):1313–1317. doi: 10.1093/rheumatology/41.11.1313. [DOI] [PubMed] [Google Scholar]
  3. Csernok Elena, Holle Julia, Hellmich Bernhard, Willem Jan, Tervaert Cohen, Kallenberg Cees G. M., Limburg Peter C., Niles John, Pan Gouli, Specks Ulrich. Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study. Rheumatology (Oxford) 2003 Oct 29;43(2):174–180. doi: 10.1093/rheumatology/keh028. [DOI] [PubMed] [Google Scholar]
  4. Hagen E. C., Daha M. R., Hermans J., Andrassy K., Csernok E., Gaskin G., Lesavre P., Lüdemann J., Rasmussen N., Sinico R. A. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int. 1998 Mar;53(3):743–753. doi: 10.1046/j.1523-1755.1998.00807.x. [DOI] [PubMed] [Google Scholar]
  5. Hanley J. A., McNeil B. J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982 Apr;143(1):29–36. doi: 10.1148/radiology.143.1.7063747. [DOI] [PubMed] [Google Scholar]
  6. Jennette J. C., Falk R. J., Andrassy K., Bacon P. A., Churg J., Gross W. L., Hagen E. C., Hoffman G. S., Hunder G. G., Kallenberg C. G. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994 Feb;37(2):187–192. doi: 10.1002/art.1780370206. [DOI] [PubMed] [Google Scholar]
  7. Leavitt R. Y., Fauci A. S., Bloch D. A., Michel B. A., Hunder G. G., Arend W. P., Calabrese L. H., Fries J. F., Lie J. T., Lightfoot R. W., Jr The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 1990 Aug;33(8):1101–1107. doi: 10.1002/art.1780330807. [DOI] [PubMed] [Google Scholar]
  8. Lim L. C., Taylor J. G., 3rd, Schmitz J. L., Folds J. D., Wilkman A. S., Falk R. J., Jennette J. C. Diagnostic usefulness of antineutrophil cytoplasmic autoantibody serology. Comparative evaluation of commercial indirect fluorescent antibody kits and enzyme immunoassay kits. Am J Clin Pathol. 1999 Mar;111(3):363–369. doi: 10.1093/ajcp/111.3.363. [DOI] [PubMed] [Google Scholar]
  9. Luqmani R. A., Bacon P. A., Moots R. J., Janssen B. A., Pall A., Emery P., Savage C., Adu D. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994 Nov;87(11):671–678. [PubMed] [Google Scholar]
  10. Merkel P. A., Polisson R. P., Chang Y., Skates S. J., Niles J. L. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med. 1997 Jun 1;126(11):866–873. doi: 10.7326/0003-4819-126-11-199706010-00003. [DOI] [PubMed] [Google Scholar]
  11. Savige J., Gillis D., Benson E., Davies D., Esnault V., Falk R. J., Hagen E. C., Jayne D., Jennette J. C., Paspaliaris B. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA) Am J Clin Pathol. 1999 Apr;111(4):507–513. doi: 10.1093/ajcp/111.4.507. [DOI] [PubMed] [Google Scholar]
  12. Schönermarck U., Lamprecht P., Csernok E., Gross W. L. Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. Rheumatology (Oxford) 2001 Feb;40(2):178–184. doi: 10.1093/rheumatology/40.2.178. [DOI] [PubMed] [Google Scholar]
  13. Specks U., Wiegert E. M., Homburger H. A. Human mast cells expressing recombinant proteinase 3 (PR3) as substrate for clinical testing for anti-neutrophil cytoplasmic antibodies (ANCA). Clin Exp Immunol. 1997 Aug;109(2):286–295. doi: 10.1046/j.1365-2249.1997.4561353.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Wang G., Csernok E., de Groot K., Gross W. L. Comparison of eight commercial kits for quantitation of antineutrophil cytoplasmic antibodies (ANCA). J Immunol Methods. 1997 Oct 27;208(2):203–211. doi: 10.1016/s0022-1759(97)00154-3. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES